Erythrocyte adenosine deaminase overproduction in hereditary hemolytic anemia

Chottiner, E G; Ginsburg, David; Tartaglia, Anthony P.; Mitchell, Beverly S.

doi:10.1182/blood.v74.1.448.448

Cited by 11 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in normal levels of ADA have been reported in a wide variety of pathologies . For example, alterations in the amount of one or both isoenzymes have been observed in a number of diseases such as hereditary hemolytic and Diamond Blackfan anemias, tuberculosis, systemic lupus erythematosus, inflammatory responses, rheumatoid arthritis, heart diseases, acquired immunodeficiency syndrome, autoimmunological thyroid diseases, some types of carcinoma, and neurological disorders, such as multiple sclerosis, meningitis, fibromyalgia, depression, and panic disorder …”

Section: Introductionmentioning

confidence: 99%

Moonlighting Adenosine Deaminase: A Target Protein for Drug Development

Cortés

Gracia

Moreno

et al. 2014

Medicinal Research Reviews

View full text Add to dashboard Cite

Interest in adenosine deaminase (ADA) in the context of medicine has mainly focused on its enzymatic activity. This is justified by the importance of the reaction catalyzed by ADA not only for the intracellular purine metabolism, but also for the extracellular purine metabolism as well, because of its capacity as a regulator of the concentration of extracellular adenosine that is able to activate adenosine receptors (ARs). In recent years, other important roles have been described for ADA. One of these, with special relevance in immunology, is the capacity of ADA to act as a costimulator, promoting T-cell proliferation and differentiation mainly by interacting with the differentiation cluster CD26. Another role is the ability of ADA to act as an allosteric modulator of ARs. These receptors have very general physiological implications, particularly in the neurological system where they play an important role. Thus, ADA, being a single chain protein, performs more than one function, consistent with the definition of a moonlighting protein. Although ADA has never been associated with moonlighting proteins, here we consider ADA as an example of this family of multifunctional proteins. In this review, we discuss the different roles of ADA and their pathological implications. We propose a mechanism by which some of their moonlighting functions can be coordinated. We also suggest that drugs modulating ADA properties may act as modulators of the moonlighting functions of ADA, giving them additional potential medical interest.

show abstract

Section: Introductionmentioning

confidence: 99%

Moonlighting Adenosine Deaminase: A Target Protein for Drug Development

Cortés

Gracia

Moreno

et al. 2014

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…It is stated that a large part of ADA is present in the cytoplasm of the cells and a small part in the nucleus. It has found that lymphocytes are 10 times more than erythrocytes (15,16,17).…”

Section: Introductionmentioning

confidence: 99%

Investi̇gation of Average Values of Prolidase, Adenozin Deaminase, Glutathione S-Transferase and Glutathione Reductase Enzymes in Pancreas Cancers

Ermaya

Demır

Demir

et al. 2021

Clinical and Experimental Health Sciences

View full text Add to dashboard Cite

Objective:The purpose of this study is to determine the relationship between enzymatic antioxidants such as glutathione reductase and glutathione s-transferase and prolidase and adenosine deaminase in patients diagnosed with pancreatic cancer.Methods: Prolidase, adenosine deaminase, glutathione s-transferase and glutathione reductase activities were determined spectrophotometrically in blood sera collected from patients and healthy control subjects included in the study. Results:In patients with pancreatic cancer, the mean value of glutathione reductase and glutathione s-transferase enzymes decreased, while the mean value of prolidase, and adenosine deaminase, enzyme activities increased (p <0.05). Conclusion:In this study, in which prolidase, enzyme activity was first measured in pancreatic cancer, high prolidase, activity can be evaluated as a factor that increases the risk of cancer. Prolidase, adenosine deaminase, glutathione reductase and glutathione s-transferase enzyme activities may play an important role in the etiopathogenesis of pancreatic cancer.

show abstract

“…Adenosine deaminase (ADA) is a house-keeping enzyme which catalyzes the deamination of adenosine to inosine. The clinical interest in this enzyme is related to the alteration of its activity in inherited deficiency in association with severe combined immunodeficiency disease [for a review see Martin and Gelfand, 19811, in other hematological disorders [Coleman et al, 1978;Chottiner et al, 1989;Glader and Backer, 19881, and in biological fluids of patients with tuberculosis [Ribera et al, 1987;Dwivedi et al, 19901. In addition, it was demonstrated recently that ADA is directly associated with a T-cell activation antigen, CD26 [Kameoka et al, 19931. In recent years, evidence was presented for an association between human immunodeficiency virus type 1 (HIV-1) infection and elevated levels of erythrocyte ADA in subjects with a history of drug abuse and in children born to HIV-positive mothers [Cowan et al, 1986;Casoli et al, 1988;Palomba et al, 19891.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users

Casoli

Lisa

Magnani

et al. 1995

Journal of Medical Virology

View full text Add to dashboard Cite

This study was designed to determine the prognostic value of erythrocyte adenosine deaminase (ADA) as a possible indicator of progression to AIDS, and compare this with other known cellular and serological markers. At the end of a 3-year study, a cohort of 114 human immunodeficiency virus-1 (HIV-1) seropositive intravenous drug users (IVDUs) from the five different Center for Disease Control (CDC) groups was examined in order to estimate the prognostic relevance with respect to the progression to acquired immunodeficiency syndrome (AIDS) of each of the following markers at baseline value: number and percentage of CD4+ T cells, number of CD8+ T cells, CD4+/CD8+ ratio, IgA and beta 2 microglobulin and ADA levels, and the presence of HIV antigens. Moreover, 57 IVDUs belonging to II and III CDC groups were analyzed in a follow-up study at 6-month intervals, in order to evaluate and compare the behavior of each marker over time. The prognostic significance of each marker was assessed by computing the survival distribution and the Cox analysis in a multivariate model providing the set of markers with greatest predictive value. The levels of ADA and the CD4+/CD8+ ratio showed a linear association with disease staging, whereas beta 2 microglobulin and CD4+/CD8+ ratio were the best predictors for AIDS progression. A highly significant increase in ADA and beta 2 microglobulin was observed during follow-up. The results obtained among HIV-positive IVDUs clearly indicate that the erythrocyte ADA may be considered a reliable marker of the development of HIV infection from the intermediate stages of the disease onwards.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Erythrocyte adenosine deaminase overproduction in hereditary hemolytic anemia

Cited by 11 publications

References 21 publications

Moonlighting Adenosine Deaminase: A Target Protein for Drug Development

Moonlighting Adenosine Deaminase: A Target Protein for Drug Development

Investi̇gation of Average Values of Prolidase, Adenozin Deaminase, Glutathione S-Transferase and Glutathione Reductase Enzymes in Pancreas Cancers

Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users

Contact Info

Product

Resources

About